Premium
Radiosensitizing effect of medroxyprogesterone acetate on endometrial cancer cells in vitro
Author(s) -
Huber Hans,
Husslein Peter,
Michalica Werner,
Wagenbichler Peter
Publication year - 1984
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19840915)54:6<999::aid-cncr2820540610>3.0.co;2-q
Subject(s) - medroxyprogesterone acetate , radiosensitivity , medicine , in vitro , medroxyprogesterone , explant culture , andrology , clonogenic assay , urology , endocrinology , hormone , radiation therapy , biology , biochemistry
From clinical experience it is known that medroxyprogesterone acetate (MPA) can increase the radiosensitivity of adenocarcinomas of the corpus uteri. This study investigates this phenomenon in vitro . Primary explants of highly differentiated adenocarcinomas were irradiated with or without pretreatment with MPA and compared with an untreated control group and to a group treated with MPA only. Cell culture itself was performed on an agarose medium in order to prevent overgrowth by fibroblasts. Untreated samples formed 43 ± 5 clones, explants treated with MPA only produced 39 ± 5 clones, a difference which was not statistically different; samples irradiated without pretreatment produced 16 ± 8 and samples after combined treatment 9 ± 3 clones (all values x ± SD). This numeric reduction of cell growth through preirradiation treatment with MPA was statistically significant. The effect of MPA as a radiosensitizer may be due to its potential to prolong the radiosensitive G 2 phase of the cell cycle. This effect of MPA may be useful also in other hormone‐dependent tumors.